AstraZeneca offers downbeat outlook and job cuts despite solid Q4
This article was originally published in Scrip
Executive Summary
David Brennan painted a solemn outlook today at AstraZeneca's fourth-quarter and full-year results, announcing a new round of cost-cutting at the expense of 8,000 jobs and projections of a tough 2010.